Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093158 · ClinicalTrials.gov registry record · Phase 3
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,800
- Enrollment target
NCT00093158 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 13,800 participants.
The verdict
NCT00093158, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,800 participants
- Enrollment target
Study Summary
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.
Interventions
- DRUG Angiomax (bivalirudin) anticoagulant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,800 participants |
| Start Date | 2003-08 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093158
The ClinicalTrials.gov registry entry for NCT00093158 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiomax (bivalirudin) anticoagulant is the first listed.
NCT00093158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093158 about?
NCT00093158 is a clinical study titled "Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)". The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either star...
What is the current status of trial NCT00093158?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,800 participants. The study started on 2003-08. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00093158?
The interventions under investigation include: Angiomax (bivalirudin) anticoagulant (DRUG).
Who is sponsoring clinical trial NCT00093158?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.